[Unmet medical need in RSV prevention and future prevention strategies].

Each year, there are more than 45.000 hospitalizations in France attributable to RSV. The development of a maternal vaccine and long half-life monoclonal antibodies against RSV suggests a change in prevention strategy from a small group of very high-risk children (extreme preterm infants, newborn with hemodynamically significant congenital heart disease or with other rare conditions) to all newborns in the pre-epidemic and epidemic periods or throughout all the year.